N-butyl-DL-aspartic acid | 84714-35-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-butyl-DL-aspartic acid
• 英文别名: N-Butyl-DL-asparaginsaeure；DL-Butylamino-bernsteinsaeure；N-Butyl-DL-aspartic acid；2-(butylamino)butanedioic acid
• CAS: 84714-35-2
• 化学式: C₈H₁₅NO₄
• 分子量: 189.211
• InChiKey: YNXVOMLTCHOPDJ-UHFFFAOYSA-N

物化性质

• 熔点：
  182 °C
• 沸点：
  301.3±32.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  13
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  DL-N-Butyl-asparaginsaeure-β-methylester 在 barium dihydroxide 作用下， 生成 N-butyl-DL-aspartic acid
  参考文献：
  名称：

  Syntheses of N-Alkyl-aspartic Acids and N²-Alkyl-α-asparagines

  摘要：

  DOI：

  10.1021/jo01090a015

文献信息

• SELECTIVE CASPASE INHIBITORS AND USES THEREOF
  申请人：Ahlfors Jan-Eric

  公开号：US20120157394A1

  公开（公告）日：2012-06-21

  The present invention relates to compounds of Formula I, II, IVC, VIIIC, IXC, or XC and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, II, IVC, VIIIC, IXC, or XC are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases). Processes for synthesizing tripeptides are provided.

  本发明涉及公式I、II、IVC、VIIIC、IXC或XC化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I、II、IVC、VIIIC、IXC或XC化合物在受试者中预防和/或治疗各种疾病和病状的方法，包括半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗塞、缺血性卒中、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病（例如多发性硬化症（MS）和阿尔茨海默病、帕金森病和亨廷顿病）。还提供了三肽合成的方法。
• Selective Caspase Inhibitors and Uses Thereof
  申请人：Ahlfors Jan-Eric

  公开号：US20110077190A1

  公开（公告）日：2011-03-31

  The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

  本发明涉及公式I，IA，II，HA，III或IHA的化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I，IA，II，IIA，III或IIIA的化合物防治受试者的各种疾病和病况的方法，包括半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗死、缺血性中风、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病（例如多发性硬化症（MS）和阿尔茨海默病、帕金森病和亨廷顿病）。
• Selective caspase inhibitors and uses thereof
  申请人：Genesis Technologies Limited

  公开号：US10167313B2

  公开（公告）日：2019-01-01

  The present invention relates to compounds of Formula I, IA, II, IIA, III, or IIIA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).

  本发明涉及式 I、IA、II、IIA、III 或 IIIA 的化合物及其药物用途。本发明的特定方面涉及这些化合物用于选择性抑制一种或多种 Caspase 的用途。还描述了将式 I、IA、II、IIA、III 或 IIIA 的化合物用于预防和/或治疗受试者的各种疾病和病症的方法，包括由 caspase 介导的疾病，如败血症、心肌梗塞、缺血性中风、脊髓损伤 (SCI)、创伤性脑损伤 (TBI) 和神经退行性疾病（如多发性硬化症 (MS) 和阿尔茨海默氏症、帕金森氏症和亨廷顿氏病）。
• Nu-substituted aspartic acids and their functional derivatives and process of producig them
  申请人：IG FARBENINDUSTRIE AG

  公开号：US02200220A1

  公开（公告）日：1940-05-07
• DE697802
  申请人：——

  公开号：——

  公开（公告）日：——